WESTLAKE VILLAGE, Calif. & BURLINGAME, Calif.--(BUSINESS WIRE)--Cynvenio Biosystems, Inc., and Color today announced a partnership to offer the Color Test, a hereditary cancer panel that analyzes 30 genes including BRCA1 and BRCA2 with Cynvenio’s ClearID® Breast Cancer test, a specialized next-generation sequencing (NGS) panel that interrogates 27 genes for somatic mutations in breast cancer. The combined Color and ClearID tests delivers a comprehensive approach for assessing hereditary breast cancer risk and monitoring patients at risk of disease.
Mutations in the BRCA1 and BRCA2 genes are known risk factors for breast cancer, and the Color Test also includes other genes associated with increased risk for the most common hereditary cancers, including colorectal, melanoma, ovarian, pancreatic, prostate, stomach, and uterine cancers. The Color Test includes access to board-certified genetic counseling for both clients and healthcare providers.
Cynvenio’s ClearID Breast Cancer test analyzes DNA from multiple sources in the bloodstream, including circulating tumor cells (CTC), plasma or cell-free DNA (cfDNA), and germline DNA. The ClearID test was designed for patients undergoing treatment for advanced breast cancer and those requiring follow-up testing at regular intervals after completion of therapy. The test is powered by Cynvenio’s 27-gene NGS panel, which also provides an option to test protein biomarkers, including the antigen receptor splice variant 7 (AR-V7) and PD-L1, without resampling the patient. Test results are summarized in a clear, actionable report for the physician.
“Even well into therapy too many patients do not seek BRCA testing because of concerns over cost or other reasons, which is unfortunate because BRCA status is important for evaluating treatment strategies,” said André de Fusco, Cynvenio’s Chief Executive Officer. “With this new combined offering, we have demolished the cost barrier and integrated the biology, which will expand the availability of BRCA and hereditary cancer testing to more people who could benefit from it.”
Othman Laraki, CEO and co-founder of Color added: “Empowering people and their doctors to make more informed health decisions, the Color Test has broadened the accessibility of DNA testing for hereditary cancers in an affordable, reliable, and convenient way. We are thrilled to partner with Cynvenio to make it more convenient for clinicians to receive a comprehensive report about a patient’s health status and risk factors. Cynvenio’s test provides more comprehensive information about the molecular profile of breast cancer, and together our tests provide added value to clinicians and patients.”
About Cynvenio Biosystems, Inc.
Cynvenio’s liquid biopsy testing technology is leading the way to more affordable and clinically actionable precision medicine strategies for cancer patients. Among the company’s breakthroughs are its line of ClearID® tests for greatly improved cancer detection and monitoring via a patient-friendly blood draw, and a suite of proprietary, distributable LiquidBiopsy® platforms and consumables for deployment in hospitals and third party diagnostic labs. Cynvenio is based in Westlake Village, California (Los Angeles). For more information, please visit www.cynvenio.com, www.clearidmonitoring.com and www.liquidbiopsy.com.
LiquidBiopsy® and ClearID® are registered trademarks of Cynvenio Biosystems, Inc.
Launched in April 2015, Color’s goal is to democratize access to genetic information. The Color Test is physician ordered, analyzes 30 genes related to the most common hereditary cancers (including breast, colorectal, melanoma, ovarian, pancreatic, prostate, stomach and uterine cancers) and includes board-certified genetic counseling with each test for clients and healthcare providers. Headquartered in Burlingame, CA, Color is privately held and backed by Khosla Ventures, Formation 8 and several leading angel investors. To learn more about Color, follow Color on Twitter @Color or Facebook at facebook.com/Color and visit color.com.